Improved methodology in determining melanoma mortality and selecting patients for immunotherapy
J Eur Acad Dermatol Venereol
.
2023 Jul;37(7):e843-e845.
doi: 10.1111/jdv.18951.
Epub 2023 Feb 22.
Authors
A J Dixon
1
,
H K Steinman
2
,
A Kyrgidis
3
,
H Smith
4
,
M Sladden
5
,
C Zouboulis
6
,
G Argenziano
7
,
Z Apalla
3
,
A Lallas
3
,
C Longo
8
,
A Nirenberg
1
,
C Popescu
9
,
J B Dixon
10
,
T Tzellos
11
,
C Zachary
12
,
L Cleaver
13
,
S Anderson
1
,
S Zagarella
14
,
J M Thomas
15
Affiliations
1
Australasian College of Cutaneous Oncology, Melbourne, Victoria, Australia.
2
Campbell University, Buies Creek, North Carolina, USA.
3
Aristotle University of Thessaloniki, Thessaloniki, Greece.
4
Oxford Dermatology, Perth, Western Australia, Australia.
5
University of Tasmania, Launceston, Tasmania, Australia.
6
Dessau Medical Center, Brandenburg Medical School, Dessau, Germany.
7
University of Campania, Campania, Italy.
8
University of Modena and Reggio Emilia, Modena, Italy.
9
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
10
Swinburne University of Technology, Melbourne, Victoria, Australia.
11
Arctic University of Norway, Tromsø, Norway.
12
University of California, Irvine, California, USA.
13
A.T. Still University, Kirksville, Missouri, USA.
14
University of Sydney, Sydney, New South Wales, Australia.
15
Formerly of Royal Marsden Hospital, London, UK.
PMID:
36785984
DOI:
10.1111/jdv.18951
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Immunotherapy / methods
Melanoma*
Patient Selection
Skin Neoplasms*